Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents.

Carola RongNicole E CarmonaYena L LeeRenee-Marie RagguettZihang PanJoshua D RosenblatMehala SubramaniapillaiMargarita ShekotikhinaFahad AlmathamAsem AlageelRodrigo MansurRoger C HoRoger S McIntyre

Published in: Expert opinion on drug safety (2017)

Δ9-Tetrahydrocannabinol and CBD are substrates and inhibitors of cytochrome P450 enzymatic pathways relevant to the biotransformation of commonly prescribed psychotropic agents. The high frequency and increasing use of cannabis invites the need for healthcare providers to familiarize themselves with potential DDIs in persons receiving select psychotropic agents, and additionally consuming medical marijuana and/or recreational marijuana.

Keyphrases

high frequency
healthcare
transcranial magnetic stimulation
nitric oxide
climate change
health information
human health